Is SVR linked to survival benefit in pacritinib-treated patients with myelofibrosis?
A study found that “pacritinib may offer a unique survival advantage” for patients with myelofibrosis (MF) and thrombocytopenia who achieve any spleen volume
Myeloproliferative Neoplasms
Primary Myelofibrosis
Multiple Myeloma
News
CARTITUDE-4 findings show improved health-related quality of life with cilta-cel for multiple myeloma
Results of the CARTITUDE-4 trial assessing patient-reported outcomes in those with multiple myeloma receiving the chimeric antigen receptor (CAR) T-cell therapy ciltacabtagene autoleucel
66th American Society of Hematology Annual Meeting & Exposition
MDS
Preliminary TakeAim data shows promise of emavusertib in higher-risk MDS
The IRAK-4 inhibitor emavusertib showed encouraging clinical activity in patients with higher-risk myelodysplastic syndromes (MDS), according to preliminary data from the phase 1/2
Aggressive B-Cell Lymphomas
Lymphoma
News
Presence of circulating lymphoma cells a significant adverse risk factor in DLBCL
The largest study to date evaluating the impact of circulating lymphoma cells (CL) on outcomes in patients with newly diagnosed de novo diffuse
Myeloproliferative Neoplasms
Polycythemia Vera
Orphan drug designation granted to selective JAK2 inhibitor for treatment of polycythemia vera
he US Food and Drug Administration (FDA) has granted orphan drug designation for VGT-1849A, a selective antisense oligonucleotide (ASO)-based JAK2 inhibitor for the
66th American Society of Hematology Annual Meeting & Exposition
Leukemia
News
Elias Jabbour, MD, talks about obe-cel ASH updates, FDA approval
Dr. Jabbour discusses obecabtagene autoleucel (obe-cel), an autologous CD19-directed chimeric antigen receptor (CAR)-T cell therapy, in relapsed or refractory adult B-cell acute lymphoblastic
Myelodysplastic Syndromes
News
CHMP announces positive opinion for imetelstat in lower-risk MDS treatment
The European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for imetelstat in the treatment
Leukemia
FDA green lights obe-cel in relapsed or refractory B-cell ALL
The US Food and Drug Administration (FDA) has approved obecabtagene autoleucel (obe-cel) in adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).
Chronic Myeloid Leukemia
Leukemia
News
Dasatinib, asciminib combo shows ‘promise’ for upfront treatment of Ph+ ALL
Dasatinib has shown efficacy in treating patients with Philadelphia chromosome-positive (Ph+) acute leukemia, though some patients develop resistance. The authors of a phase
